Allitinib
Based on 3 publication(s) in Google Scholar
Allitinib (AST-1306) is an orally active and irreversible EGFR and ErbB2 inhibitor with IC50s of 0.5 and 3 nM, respectively. Allitinib also inhibits ErbB4 with an IC50 of 0.8 nM. Allitinib is an anilino-quinazoline compound and has anti-cancer activity.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 98.88%
- No. CAS: 897383-62-9
- Fòrmula: C24H18ClFN4O2
- Peso molecular:448.88
-
Almacenamiento:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications Citing Use of MedChemExpress (MCE) Allitinib
MoreVer todos los productos específicos de isoformas EGFR
More
Actividad biológica
|
EGFR 0.5 nM (IC50) |
EGFRL858R/T790M 12 nM (IC50) |
ErbB2 3 nM (IC50) |
ErbB4 0.8 nM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A-431 | IC50 |
0.2 μM
Compound: AST1306
|
Antiproliferative activity against human A431 cells over-expressing EGFR gene after 72 hrs by SRB assay
Antiproliferative activity against human A431 cells over-expressing EGFR gene after 72 hrs by SRB assay
|
[PMID: 22227214] |
| A549 | IC50 |
6.2 μM
Compound: Chemical Probe: AST1306
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay
|
[PMID: 21789172] |
| A549 | IC50 |
6.8 μM
Compound: AST1306
|
Antiproliferative activity against human A549 cells over-expressing EGFR gene after 72 hrs by SRB assay
Antiproliferative activity against human A549 cells over-expressing EGFR gene after 72 hrs by SRB assay
|
[PMID: 22227214] |
| BT-474 | IC50 |
0.97 μM
Compound: Chemical Probe: AST1306
|
Antiproliferative activity against human BT-474 cells assessed as reduction in cell viability after 72 hrs by SRB assay
Antiproliferative activity against human BT-474 cells assessed as reduction in cell viability after 72 hrs by SRB assay
|
[PMID: 21789172] |
| Calu-3 | IC50 |
0.23 μM
Compound: Chemical Probe: AST1306
|
Antiproliferative activity against human Calu-3 cells assessed as reduction in cell viability after 72 hrs by SRB assay
Antiproliferative activity against human Calu-3 cells assessed as reduction in cell viability after 72 hrs by SRB assay
|
[PMID: 21789172] |
| MCF7 | IC50 |
16 μM
Compound: Chemical Probe: AST1306
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by SRB assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by SRB assay
|
[PMID: 21789172] |
| MDA-MB-468 | IC50 |
6.2 μM
Compound: Chemical Probe: AST1306
|
Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell viability after 72 hrs by SRB assay
Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell viability after 72 hrs by SRB assay
|
[PMID: 21789172] |
| NCI-H1975 | IC50 |
0.7 μM
Compound: AST1306
|
Antiproliferative activity against human NCI-H1975 cells over-expressing EGFR mutant gene after 72 hrs by SRB assay
Antiproliferative activity against human NCI-H1975 cells over-expressing EGFR mutant gene after 72 hrs by SRB assay
|
[PMID: 22227214] |
| NCI-H23 | IC50 |
6.2 μM
Compound: Chemical Probe: AST1306
|
Antiproliferative activity against human NCI-H23 cells assessed as reduction in cell viability after 72 hrs by SRB assay
Antiproliferative activity against human NCI-H23 cells assessed as reduction in cell viability after 72 hrs by SRB assay
|
[PMID: 21789172] |
| SK-OV-3 | IC50 |
6.2 μM
Compound: Chemical Probe: AST1306
|
Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell viability after 72 hrs by SRB assay
Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell viability after 72 hrs by SRB assay
|
[PMID: 21789172] |
AST1306 (AST-1306; 0.19-6.25 μM; 72 hours) induces a significant, concentration-dependent inhibition of the growth of HIH3T3-EGFR T790M/L858R cells[1].
AST1306 inhibits the activation of tyrosine kinases and downstream signaling pathways in A549 cells, Calu-3 cells and SK-OV-3 cells. AST1306 dose-dependently and markedly inhibits EGF-induced EGFR phosphorylation in A549 cells[1].
AST1306 (0.1, 0.5, 1.0, 5.0 μM) can dramatically inhibit the growth of both tumor cells on soft agar, and SK-OV-3 cells exhibited much more sensitivity than that of A549 cells[1].
AST1306 (0.001-1.0 μM; 4 hours) is more than 3000-fold selective for ErbB family kinases over other kinase families[1].
AST1306 potently inhibits the EGFR T790M/L858R double mutant, exhibiting an IC50 value of 12 nM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:NIH3T3 parental cells and NIH3T3 cells
-
Concentration:0.19, 0.39, 0.78, 1.56, 3.13, 6.25 μM
-
Incubation Time:72 hours
-
Result:Induced a significant, concentration-dependent inhibition of the growth of HIH3T3-EGFR T790M/L858R cells.
-
Cell Line:A549 cells , Calu-3 cells and SK-OV-3 cells
-
Concentration:0.001, 0.01, 0.1, 1.0 μM
-
Incubation Time:4 hours
-
Result:Inhibits the activation of tyrosine kinases and downstream signaling pathways.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nude mice with SK-OV-3 and Calu-3 tumors[1]
-
Dosage:25, 50, 100 mg/kg
-
Administration:p.o; twice daily; for 28 days
-
Result:Caused a dramatic suppression of tumor growth.
Chemical Information
-
No. CAS 897383-62-9
-
Appearance Solid
-
Peso molecular 448.88
-
Fòrmula C24H18ClFN4O2
-
Color Off-white to light yellow
-
SMILES
FC1=CC=CC(COC2=C(Cl)C=C(NC3=NC=NC4=C3C=C(NC(C=C)=O)C=C4)C=C2)=C1
-
Synonyms
AST-1306; ALS 1306
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Sci Adv
Tissue-specific inflammation induces cell state plasticity with oncogenic addiction in mucosal melanoma. [Abstract]2026 Apr 3;12(14):eady4536. PMID: 41920996 -
Cell Rep
2025 Apr 16;44(5):115572. PMID: 40249703 -
Sci Data
High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma. [Abstract]2024 Sep 19;11(1):1024. PMID: 39300112
Solvente y solubilidad
DMSO : 100 mg/mL (222.78 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2 mg/mL (4.46 mM); Clear solution
This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (277 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2278 mL | 11.1388 mL | 22.2777 mL | 55.6942 mL |
| 5 mM | 0.4456 mL | 2.2278 mL | 4.4555 mL | 11.1388 mL | |
| 10 mM | 0.2228 mL | 1.1139 mL | 2.2278 mL | 5.5694 mL | |
| 15 mM | 0.1485 mL | 0.7426 mL | 1.4852 mL | 3.7129 mL | |
| 20 mM | 0.1114 mL | 0.5569 mL | 1.1139 mL | 2.7847 mL | |
| 25 mM | 0.0891 mL | 0.4456 mL | 0.8911 mL | 2.2278 mL | |
| 30 mM | 0.0743 mL | 0.3713 mL | 0.7426 mL | 1.8565 mL | |
| 40 mM | 0.0557 mL | 0.2785 mL | 0.5569 mL | 1.3924 mL | |
| 50 mM | 0.0446 mL | 0.2228 mL | 0.4456 mL | 1.1139 mL | |
| 60 mM | 0.0371 mL | 0.1856 mL | 0.3713 mL | 0.9282 mL | |
| 80 mM | 0.0278 mL | 0.1392 mL | 0.2785 mL | 0.6962 mL | |
| 100 mM | 0.0223 mL | 0.1114 mL | 0.2228 mL | 0.5569 mL |